Bulking Agent Injections Effective in Fecal IncontinenceLast Updated: March 18, 2011. A transanal submucosal injection of dextranomer in stabilized hyaluronic acid is an effective treatment for fecal incontinence, according to a study published in the March 19 issue of The Lancet.
FRIDAY, March 18 (HealthDay News) -- A transanal submucosal injection of dextranomer in stabilized hyaluronic acid (NASHA Dx) is an effective treatment for fecal incontinence, according to a study published in the March 19 issue of The Lancet.
Wilhelm Graf, Ph.D., from the Akademiska Sjukhuset in Uppsala, Sweden, and colleagues assessed the efficacy of transanal submucosal injections of NASHA Dx for the treatment of fecal incontinence. Of the 206 patients, aged 18 to 75 years, with fecal incontinence who were included in the study, 136 were randomly assigned to receive transanal submucosal injections of NASHA Dx and 70 received sham. The severity of fecal incontinence and quality of life were assessed at six months by clinical assessments and patient diaries. A 50 percent or greater reduction in the number of incontinence episodes was the primary end point of the study. Patients in the active treatment group were still being followed up at the time of publication.
The investigators found that 52 percent of patients who received NASHA Dx experienced a 50 percent or more reduction in the number of incontinence episodes compared to 31 percent of patients who received sham treatment (odds ratio, 2.36). A total of 128 treatment-related adverse events were recorded, including one rectal abscess and one prostatic abscess, both of which were serious.
"Submucosal injection of NASHA Dx provided a substantial improvement in incontinence symptoms when compared with baseline and with sham treatment," the authors write.
Several authors disclosed financial relationships with Q-Med AB, which funded the study.
|Previous: CDC: HIV Transmitted Through Living Kidney Donation||Next: Stem Cells Linked to Functional Recovery of Heart Post MI|
Reader comments on this article are listed below. Review our comments policy.